Park Ha Biological Technology is trading at $0.33, down 10.9% following headlines of a new class-action lawsuit alleging a fraudulent stock promotion scheme.
- Pre-market traders are reacting to heightened legal risk and potential reputational damage stemming from the allegations.
- The downward move extends the stock's recent volatility, reversing momentum from a modest gain recorded on July 31, 2026.